Top Story

Weekly prophylaxis with nonacog beta pegol safe, effective for hemophilia B

October 31, 2014

Nonacog beta pegol effectively treated bleeding episodes and was associated with low annualized bleeding rates in patients with hemophilia B, according to study results.

Peter W. Collins, MD, of the Arthur Bloom Hemophilia Center at Cardiff University in the United Kingdom, and colleagues sought to evaluate the safety and efficacy of nonacog beta pegol (N9-GP, Novo Nordisk) — a recombinant glycoPEGylated Factor IX with an extended half-life — in 74 previously treated patients with hemophilia B.

FDA approvals

FDA approves Obizur for acquired hemophilia A

October 24, 2014
The FDA approved Obizur for the treatment of bleeding disorders in adults with acquired hemophilia A.The development of acquired hemophilia A — a non-genetic…
In the Journals

Efficacy of VTE chemoprophylaxis in otolaryngology patients varied by subgroup

October 24, 2014
The efficacy and safety of venous thromboembolism chemoprophylaxis for individuals undergoing otolaryngologic surgery varied based on Caprini risk score and the type of…
In the Journals

Recombinant Factor VIII product increased inhibitor development risk

October 24, 2014
One recombinant Factor VIII product was associated with an increased risk for inhibitor formation compared with similar products for the treatment of severe hemophilia…
CME
figure

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
CME CNE
figure

Treatment Decision-Making through the Spectrum of MDS: Case 1 Low Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain MDS…
More »

Filter By:

In the Journals

Weekly prophylaxis with nonacog beta pegol safe, effective for hemophilia B

October 31, 2014
Nonacog beta pegol effectively treated bleeding episodes and was associated with low annualized bleeding rates in patients with hemophilia B…
FDA approvals

FDA approves Obizur for acquired hemophilia A

October 24, 2014
The FDA approved Obizur for the treatment of bleeding disorders in adults with acquired hemophilia A.The development of acquired hemophilia A —…
In the Journals

Efficacy of VTE chemoprophylaxis in otolaryngology patients varied by subgroup

October 24, 2014
The efficacy and safety of venous thromboembolism chemoprophylaxis for individuals undergoing otolaryngologic surgery varied based on Caprini risk…
In the Journals

Recombinant Factor VIII product increased inhibitor development risk

October 24, 2014
One recombinant Factor VIII product was associated with an increased risk for inhibitor formation compared with similar products for the treatment of…
figure Institution Notes

ASH elects four executive committee members

October 18, 2014
ASH elected four new members to its executive committee, the organization’s governing body.Kenneth C. Anderson, MD, will serve a 1-year term as…
figure In the Journals

Hydroxyurea, transfusions urged for sickle cell disease management

October 17, 2014
The use of hydroxyurea and transfusion therapy is “strongly recommended” for patients with sickle cell disease, according to an…
In the Journals

Modified gene therapy shows promise in SCID-X1

October 8, 2014
A majority of boys with X-linked severe combined immunodeficiency experienced T-cell recovery and infection clearance after undergoing gene therapy…
In the Journals

Eclampsia, acute systemic infection increased risk for postpartum VTE

October 8, 2014
Women with preeclampsia/eclampsia and postpartum acute systemic infection experienced the greatest risk for developing venous thromboembolism during…
In the Journals

Somatic mutations linked to malignant transformation of aplastic anemia

October 6, 2014
Somatic mutations in patients with aplastic anemia were associated with longer disease duration and an increased risk for transformation to…
FDA News

FDA grants fast track designation to NKTT120 for sickle cell disease

October 2, 2014
The FDA granted fast track designation to NKTT120 as a potential treatment for patients with sickle cell disease, the drug’s manufacturer…
More Headlines »